Skip to content

The Readiness of Psychiatrists to Implement Psychedelic-Assisted Psychotherapy

Ahmad Rehman, Habib Syed, Kathryn Forcer, Graham Campbell, Lisa Page

Frontiers in Psychiatry November 26, 2021 DOI: 10.3389/fpsyt.2021.743599 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Mixed-methods pilot study using a cross-sectional survey and focus groups Peer reviewed
Sample size 83
Population NHS psychiatrists of all levels in one mental health trust
Topics Psychedelic-assisted therapy
Keywords Thematic analysis Focus group Mainstream Mental health Preparedness Openness to experience Psychotherapist
Citations 40
Key findings Most NHS psychiatrists are positive about psychedelic-assisted therapy but lack preparedness and confidence to implement it, with significant training needs identified.

Abstract

Introduction: Psychedelic-assisted psychotherapy is a promising approach in psychiatry; evidence is growing and it may not be long before mainstream services are expected to offer it to selected patients. This pilot study examined the attitudes and knowledge of NHS psychiatrists of all levels towards psychedelic-assisted psychotherapy and explored potential barriers and facilitators to its implementation.

Methods: A mixed-methods approach was adopted, using a cross-sectional survey and focus groups. All psychiatrists in one NHS mental health trust were approached by email to participate. The survey was analysed using a simple descriptive approach and thematic analysis was used for the focus groups.

Results: Eighty-three (25.7%) psychiatrists participated in the survey. All psychiatrists were familiar with one or more psychedelic substances. Although 77.2% felt that there should be a role for controlled or therapeutic use of psychedelics, trainees appeared better informed than non-training grade psychiatrists. Psychiatrists of all grades did not feel prepared to participate in the delivery of psychedelic-assisted psychotherapy. Thematic analysis of the focus groups identified three main themes in relation to psychedelic-assisted psychotherapy: “ need for knowledge ,” “ openness to change ,” and “ uncertainty .”

Discussion: NHS psychiatrists are positive about the potential for psychedelic-assisted therapy to advance psychiatric practise. However, psychiatrists are lacking in confidence or preparedness to implement this treatment should it become a mainstream option and significant training needs were identified. Thematic analysis highlighted the need for societal shifts as well as professional ones.

Comparable studies

Other non-randomized and open-label trials on psychedelic-assisted therapy, most cited first.

Study Year Design Participants
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Patients with severe, unipolar, treatment-resistant major depression 2017 Open-label trial n = 20
Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study. Adults with chronic, treatment-resistant PTSD 2013 Long-term follow-up of a completed trial n = 19
Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. Patients with major depressive disorder 2021 Open-label study n = 24
Ketamine Psychedelic Therapy (KPT): A Review of the Results of Ten Years of Research Alcoholic patients 1997 Controlled clinical trial n = 211
Exploratory study of the dose-related safety, tolerability, and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder. Treatment-resistant individuals with major depressive disorder (MDD) and healthy controls 2022 Open-label, fixed-order, dose-escalation exploratory phase 1 study n = 10

Citations in the library

Cited by 36

and 31 more in the library

Cites 15

and 10 more in the library

Explore topics